Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Eur J Clin Pharmacol ; 47(3): 247-52, 1994.
Article in English | MEDLINE | ID: mdl-7867677

ABSTRACT

The acute and chronic effects on blood coagulation and fibrinolysis of a new molecular weight dermatan sulphate (Desmin 370) have been investigated in a double blind, placebo-controlled cross over study in 12 healthy volunteers. The compound (100 and 200 mg) was injected IM and the expected heparin cofactor II potentiating effect, reflecting dermatan sulphate activity, peaked after 2 h and was still detectable after 9 h. Surprisingly for this type of compound, a substantial increase in anti-Xa activity also appeared and lasted up to 12 h in the absence of a significant change in aPTT. The bovine-thrombin time was not changed, while human-thrombin times were slightly, albeit non-significantly, prolonged. The activity of t-PA was increased 6h after the higher dose, but the overall pattern of fibrinolytic activities did not suggest any important change after drug treatment in comparison to placebo. No residual or cumulative effect on any of the investigated parameters was detectable 24 h after the injection on the 4th and 8th days during repeated daily administration. Parallel in vitro and in vivo investigations showed that the unexpected anti-Xa effect was not attributable to contamination by traces of low molecular weight heparin. Desmin 370, a low molecular weight dermatan sulphate that potentiates heparin cofactor II and also inhibits Factor Xa, deserves clinical evaluation as an antithrombotic agent.


Subject(s)
Blood Coagulation/drug effects , Dermatan Sulfate/pharmacology , Fibrinolysis/drug effects , Adolescent , Adult , Cross-Over Studies , Dermatan Sulfate/adverse effects , Dermatan Sulfate/pharmacokinetics , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Injections, Intramuscular , Male , Time Factors
2.
Arzneimittelforschung ; 43(2): 119-22, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8457236

ABSTRACT

The acute and chronic effects of a preparation of dried garlic powder (Sapec) in a total daily dose of 900 mg on fibrinolysis and platelet aggregation have been evaluated in a randomized, double-blind, placebo controlled cross-over study of 12 healthy subjects. Total euglobulin fibrinolytic activity and t-PA (tissue plasminogen activator) activity were significantly higher 4 and 6 h after garlic and placebo ingestion, and no differences were recorded between treatments. After 14 days of treatment, t-PA activity was significantly higher after garlic, with inter-treatment significance. No significant changes in PAI (Plasminogen Activator Inhibitor) activity and fibrinogen levels were recorded. Platelet aggregation induced by adenosine diphosphate and collagen, and especially beta-thromboglobulin (beta-TG) release after collagen stimulation were significantly inhibited 2 and 4 h after garlic ingestion; platelet aggregation values were also significantly lower after 7 and 14 days of garlic treatment. No significant changes were found in adenosine triphosphate release and serum TXB2 levels after acute garlic administration.


Subject(s)
Fibrinolysis/drug effects , Garlic , Plants, Medicinal , Platelet Aggregation/drug effects , Adenosine Diphosphate/pharmacology , Adenosine Triphosphate/blood , Adult , Blood Coagulation/drug effects , Blood Platelets/drug effects , Blood Platelets/metabolism , Collagen/pharmacology , Double-Blind Method , Humans , In Vitro Techniques , Male , Plasminogen Activators/metabolism , Plasminogen Inactivators/metabolism , Platelet Function Tests , Thromboxane B2/blood , beta-Thromboglobulin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...